Known targets — ChEMBL curated mechanism
DRD4HTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3E
The experimentally established mechanism targets of Clothiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 1.00 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 6/20 | 0.62 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.55 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clothiapine SCHEMBL122941 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD3HRH1DRD1 | |
| Clothiapine SCHEMBL27848972 | 0.87 | DRD2 (0.76) | DRD2CHRM1DRD3HRH1DRD1 | |
| Metiapine SCHEMBL29710898 | 0.86 | DRD2 (0.76) | DRD2CHRM1DRD3HRH1DRD1 | |
| Metiapine SCHEMBL121263 | 0.86 | DRD2 (0.76) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL144624 | 0.86 | DRD2 (0.74) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL9377234 | 0.85 | DRD2 (1.00) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL14631841 | 0.85 | DRD2 (1.00) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL7403485 | 0.85 | DRD2 (0.74) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL9211771 | 0.84 | DRD2 (0.72) | DRD2CHRM1DRD3HRH1DRD1 | |
| SCHEMBL9094940 | 0.83 | DRD2 (0.72) | DRD2CHRM1DRD3HRH1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-11607510-B2 | Methods and devices for controlled drug vaporization | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-03-21 | — | — | US | disclosed |
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | LEYDEN TECHNOLOGIES B.V. (NL) | 2022-12-06 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220023551-A1 | METHODS AND DEVICES FOR CONTROLLED DRUG VAPORIZATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | TPH1, BDNF, TPH2 | HTR2A 19/4885HTR2C 7/4885HTR2B 40/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | HTR2A 520/4885HTR2C 405/4885HTR2B 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.